Tirzepatide

Unassigned

New Medicines

Type 2 diabetes mellitus

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Dual glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor agonist (first in class)
Currently 3.8 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 1 million people with type 2 diabetes have not yet been diagnosed [6].
Type 2 diabetes mellitus
Subcutaneous injection